| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a92803f6cf472da3edb056e6ddcf5fb5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-035
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6801
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2833 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 |
| filingDate |
2022-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc561d301194f4c022c1c8b886e92a4b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7db0471c69e1392429ba3890dfc32e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15681a6c013a67e4002c2228d4109b2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7754c01f493217876393e028e5e5851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef979c0d542ce127186ea29bcb036960 |
| publicationDate |
2022-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2022256131-A1 |
| titleOfInvention |
T cell receptors |
| abstract |
The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide nGVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may ncomprise non-natural mutations within the alpha and/or beta variable domains relative to a native nMAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel nimmunotherapeutic reagents for the treatment of malignant disease. |
| priorityDate |
2016-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |